PEDIATRIC EYE DISEASE INVESTIGATOR GROUP: CHAIR'S OFFICE

描述(由申请人提供)：本网络主席办公室申请是3个平行申请之一，申请将儿童眼病研究小组(PEDIG)的资金延长五年。自1997年成立以来，PEDIG已经进行了4个斜视方案，19个弱视方案，3个鼻泪管阻塞方案，2个近视/远视方案，以及几个试点研究。到本申请申请的资金申请开始时，预计3个新方案将在当前周期中启动：评估收敛功能不全治疗的随机试验、比较肉毒毒素与内斜视切开手术的随机试验以及评估幼年型特发性关节炎儿童葡萄膜炎发病率的临床疾病登记。尽管取得了这些成就，但在儿科眼科护理和斜视方面仍存在许多重要的问题和争议。PEDIG已经开发或将开发临床试验，以解决其中许多问题。这些包括：(1)尽管接受了最大限度的弱视治疗，但仍有视力缺陷的儿童的治疗策略；(2)为幼儿远视开眼镜与不开眼镜的效果；(3)间歇性外斜视的最佳手术和非手术治疗；(4)白内障手术后并发症的危险因素；以及(5)最佳治疗方法。 对于收敛不足。PEDIG下一个五年资助期的具体目标是：(1)完成预计在资助期开始时正在进行的7项方案，(2)在目前管理层没有得到证实的理由的常见儿科眼病中启动10项新方案，(3)通过征集新的地点和研究人员的参与并鼓励年轻研究人员参与，继续扩大PEDIG网络，(4)继续教育儿科眼科医生、儿科视光师和临床研究协调员关于临床试验和良好的临床研究实践的原则，(5)培养儿童眼科医生和儿童验光师成为临床试验和临床研究的领导者，以及(6)开发进行未来弱视和斜视试验所需的新方法和结果措施。

DESCRIPTION (provided by applicant): This Network Chair's Office application is one of 3 parallel applications for a five-year extension of funding for the Pediatric Eye Disease Investigator Group (PEDIG). Since its inception in 1997, PEDIG has conducted 4 protocols in strabismus, 19 protocols in amblyopia, 3 protocols in nasolacrimal duct obstruction, 2 protocols in myopia/hyperopia, and several pilot studies. By the time the funding requested in this application would begin, it is expected that 3 new protocols will have started in the current cycle a randomized trial to evaluate treatment for convergence insufficiency, a randomized trial to compare botulinum toxin with incisional surgery for esotropia, and a clinical disease registry to evaluate uveitis incidence in children with juvenile idiopathic arthritis. Despite these accomplishments, many important questions and controversies remain in pediatric eye care and strabismus. PEDIG has developed, or will be developing, clinical trials to address many of these questions. These include: (1) treatment strategies for children with a visual deficit despite maximal amblyopia treatment, (2) the effect of prescribing versus not prescribing spectacles for hyperopia in young children, (3) the best surgical and non-surgical treatments for intermittent exotropia, (4) risk factors for complications after cataract surgery, and (5) the optimal treatment for convergence insufficiency. Specific aims for the next 5-year funding period for PEDIG are to: (1) complete the 7 protocols that are expected to be in progress at the time the funding period begins, (2) initiate 10 new protocols in common pediatric eye disorders where the current management does not have a proven rationale, (3) continue to expand the PEDIG network by soliciting the participation of new sites and investigators and encouraging the involvement of young investigators, (4) continue to educate pediatric ophthalmologists, pediatric optometrists, and clinical research coordinators on the principles of clinical trials and good clinical research practices, (5) train pediatric ophthalmologists and pediatric optometrists to be leaders in clinica trials and clinical research, and (6) develop new methods and outcome measures needed to conduct future amblyopia and strabismus trials.